Anti-CD7 drugs that are currently being evaluated in clinical trials are CAR-T and CAR-NK cell drugs for T-ALL [119,120,121,122] and a combination of Ricin-conjugated anti-CD3/CD7 immunotoxins for GvHD [123]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.